DK2714888T3 - Rekombinant gær - Google Patents
Rekombinant gærInfo
- Publication number
- DK2714888T3 DK2714888T3 DK12727897.6T DK12727897T DK2714888T3 DK 2714888 T3 DK2714888 T3 DK 2714888T3 DK 12727897 T DK12727897 T DK 12727897T DK 2714888 T3 DK2714888 T3 DK 2714888T3
- Authority
- DK
- Denmark
- Prior art keywords
- iron
- disorders
- methods
- presented
- treating
- Prior art date
Links
- 208000016286 Iron metabolism disease Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000000546 Apoferritins Human genes 0.000 abstract 1
- 108010002084 Apoferritins Proteins 0.000 abstract 1
- 206010022971 Iron Deficiencies Diseases 0.000 abstract 1
- 206010065973 Iron Overload Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/114,429 US8778878B2 (en) | 2007-01-29 | 2011-05-24 | Use of ferritin to treat iron disorders |
| PCT/GB2012/000461 WO2012160333A2 (en) | 2011-05-24 | 2012-05-24 | Recombinant yeast |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2714888T3 true DK2714888T3 (da) | 2018-01-29 |
Family
ID=46317426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12727897.6T DK2714888T3 (da) | 2011-05-24 | 2012-05-24 | Rekombinant gær |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8778878B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2714888B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014516535A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103635570A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012260682B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013029769B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2874042C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2714888T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2659185T3 (cg-RX-API-DMAC7.html) |
| NO (1) | NO2714888T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2714888T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012160333A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10249552A1 (de) | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
| KR101905340B1 (ko) | 2006-01-06 | 2018-10-05 | 루이트폴드 파머수티컬스, 인코퍼레이티드 | 철을 투여하기 위한 방법 및 조성물 |
| US8778878B2 (en) * | 2007-01-29 | 2014-07-15 | Chyna, LLC | Use of ferritin to treat iron disorders |
| WO2016027264A1 (en) * | 2014-08-21 | 2016-02-25 | Ramot At Tel-Aviv University Ltd. | Targeted liposomes encapsulating iron complexes and their uses |
| KR101811050B1 (ko) * | 2015-09-02 | 2017-12-21 | 경북대학교 산학협력단 | 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물 |
| CN108503704A (zh) | 2017-02-27 | 2018-09-07 | 昆山新蕴达生物科技有限公司 | 穿越血脑屏障的纳米药物载体 |
| KR20210023907A (ko) * | 2018-06-04 | 2021-03-04 | 시데로 바이오사이언스 엘엘씨 | 철 대사작용 및 소화관 마이크로바이옴 건강을 개선시키기 위한 조성물 및 방법 |
| WO2020239809A1 (en) * | 2019-05-28 | 2020-12-03 | Previpharma Consulting Gmbh | Method for preparing iron-depleted ferritin and use thereof |
| CN110759986B (zh) * | 2019-10-18 | 2023-01-31 | 大连工业大学 | 一种可逆自组装蛋白的高效制备方法 |
| CN117642083A (zh) * | 2021-05-19 | 2024-03-01 | 赛德罗生物科学有限责任公司 | 铁蛋白组合物耐受性 |
| KR102691733B1 (ko) * | 2021-10-13 | 2024-08-05 | 전북대학교산학협력단 | 효모 유래 액포를 유효성분으로 포함하는 퇴행성 신경계 질환의 예방 또는 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100419530B1 (ko) * | 2000-11-15 | 2004-02-19 | 주식회사 알엔에이 | 재조합 메탄올 자화 효모를 이용한 인간 페리틴의 대량생산 방법 |
| KR100545981B1 (ko) * | 2003-04-08 | 2006-01-25 | 전북대학교산학협력단 | 이종중합형 패리틴 생산방법 |
| FR2898132B1 (fr) * | 2006-03-01 | 2012-09-28 | Mane Fils V | Systeme d'expression d'un gene d'interet chez la levure |
| US8071542B2 (en) * | 2007-01-29 | 2011-12-06 | Chyna, LLC | Use of ferritin to treat iron deficiency disorders |
| US8778878B2 (en) * | 2007-01-29 | 2014-07-15 | Chyna, LLC | Use of ferritin to treat iron disorders |
| AU2008353469B2 (en) * | 2008-03-28 | 2014-12-11 | Chyna Llc | Use of ferritin to treat iron deficiency disorders |
-
2011
- 2011-05-24 US US13/114,429 patent/US8778878B2/en active Active
-
2012
- 2012-05-24 JP JP2014511946A patent/JP2014516535A/ja active Pending
- 2012-05-24 BR BR112013029769-7A patent/BR112013029769B1/pt active IP Right Grant
- 2012-05-24 ES ES12727897.6T patent/ES2659185T3/es active Active
- 2012-05-24 DK DK12727897.6T patent/DK2714888T3/da active
- 2012-05-24 CA CA2874042A patent/CA2874042C/en active Active
- 2012-05-24 CN CN201280024378.4A patent/CN103635570A/zh active Pending
- 2012-05-24 PL PL12727897T patent/PL2714888T3/pl unknown
- 2012-05-24 WO PCT/GB2012/000461 patent/WO2012160333A2/en not_active Ceased
- 2012-05-24 NO NO12727897A patent/NO2714888T3/no unknown
- 2012-05-24 EP EP12727897.6A patent/EP2714888B1/en active Active
- 2012-05-24 AU AU2012260682A patent/AU2012260682B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012260682B2 (en) | 2015-07-30 |
| EP2714888A2 (en) | 2014-04-09 |
| US20110287033A1 (en) | 2011-11-24 |
| PL2714888T3 (pl) | 2018-06-29 |
| US8778878B2 (en) | 2014-07-15 |
| CA2874042C (en) | 2020-10-06 |
| WO2012160333A2 (en) | 2012-11-29 |
| BR112013029769A2 (pt) | 2017-06-06 |
| CA2874042A1 (en) | 2012-11-29 |
| NO2714888T3 (cg-RX-API-DMAC7.html) | 2018-03-24 |
| CN103635570A (zh) | 2014-03-12 |
| ES2659185T3 (es) | 2018-03-14 |
| JP2014516535A (ja) | 2014-07-17 |
| WO2012160333A3 (en) | 2013-03-07 |
| BR112013029769B1 (pt) | 2021-09-28 |
| AU2012260682A1 (en) | 2013-05-02 |
| EP2714888B1 (en) | 2017-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2714888T3 (da) | Rekombinant gær | |
| WO2012062925A3 (en) | Compounds and methods for treating pain | |
| WO2013061161A3 (en) | New combination therapies for treating neurological disorders | |
| PH12012501838A1 (en) | Aptamers to ã-ngf and their use in treating ã-ngf mediated diseases and disorders | |
| MX2015001250A (es) | Composiciones y tratamiento para enfermedades y trastornos del ojo. | |
| WO2012145651A3 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| WO2016106403A3 (en) | Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21 | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| HK1210599A1 (en) | Abuse deterrent pharmaceutical compositions for controlled release | |
| PH12013500577A1 (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| EA201590880A1 (ru) | Композиции и способы лечения протеинопатий | |
| MY184241A (en) | Human antibodies to gfr?3 and methods of use thereof | |
| WO2014080286A3 (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
| WO2014153385A3 (en) | Methods of treating metabolic disorders | |
| IN2014MN02269A (cg-RX-API-DMAC7.html) | ||
| WO2013087654A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
| EA201492102A1 (ru) | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны | |
| PH12014500250A1 (en) | Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
| GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
| EP4302825A3 (en) | Pharmaceutical compositions for treatment of inappetence | |
| MX2013015347A (es) | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). | |
| HK1213175A1 (zh) | Tspo介导的疾病和/或病症的治疗和/或预防 | |
| MX2020001428A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| BR112014004737A2 (pt) | composto de composição de cloridrato de ambroxol e método de preparação do composto | |
| HK1211239A1 (en) | Treatment regimens |